文献速递生殖医学妇科

揭示人血小板裂解液增强子宫内膜容受性的分子机制

Unveiling the molecular mechanisms of human platelet lysate in enhancing endometrial receptivity.
PubMed 文献 · Hum Reprod · 2025-01-01

该横断面研究纳入5例非复发性种植失败(RIF)对照和18例RIF患者(含薄型子宫内膜亚组),用1%或10%人血小板裂解液(HPL)处理原代子宫内膜细胞48小时。HPL促进上皮和基质细胞增殖,上调细胞周期与细胞外基质重塑通路,并增加滋养层球体附着率。

要点

  • HPL处理48小时使所有组上皮细胞增殖增加1.24至1.49倍(P<0.05)。
  • HPL使RIF组滋养层球体附着率从42.58%升至68.90%(增加26%,P<0.01)。
  • HPL使RIF+薄型子宫内膜组附着率从57.52%升至86.5%(增加29%,P<0.01)。

核心结论

  • HPL通过激活细胞增殖、调节细胞间信号传导和细胞外基质组织,刺激子宫内膜生长并促进滋养层附着。

研究设计与样本

  • 横断面研究(对照与治疗比较),纳入5例非RIF对照和18例RIF患者(其中RIF组和RIF合并薄型子宫内膜组为两个亚组)。
  • 子宫内膜组织取自加拿大多伦多CReATe生育中心32至47岁绝经前女性的常规活检。
  • 原代子宫内膜上皮细胞(EEC)和基质细胞(ESC)分别培养,用无血清培养基(SFM)或含1%HPL(EEC)或10%HPL(ESC)的SFM处理48小时。

主要发现

  • HPL处理48小时使所有组EEC增殖增加1.24至1.49倍(P<0.05)。
  • ESC在增殖期RIF组增殖增加1.29倍,在分泌期RIF+薄型子宫内膜组增加1.92倍(P<0.05)。
  • HPL上调EEC中45个基因(包括MMP1、MMP9、ADAMTS18),上调ESC中378个基因(如BUB1、CDK1、MKI67、PLK1),两种细胞共有22个基因上调。
  • HPL下调EEC中30个基因(包括KL、ADRA2A),下调ESC中429个基因(如PTGIS、PTGDS、PTGES),共有7个基因下调。
  • 与未处理对照相比,HPL增加原代EEC对滋养层球体的附着:RIF培养从42.58%升至68.90%(增加26%,P<0.01),RIF+薄型子宫内膜培养从57.52%升至86.5%(增加29%,P<0.01)。

关键数值与推荐

  • 差异表达基因判定标准为log2FoldChange绝对值大于2且Padj<0.05。
  • 通路富集分析使用Enrichr(Reactome 2022数据库)。
  • 测序数据存放于GEO登录号GSE279514。

临床怎么用

  • 作者认为这些体外发现提示HPL可能对RIF和薄型子宫内膜有效,但需在体内验证。
  • 作者指出需要随机对照试验评估和比较商业HPL作为aPRP治疗替代方案的疗效。
  • 作者认为该研究通过明确参与的细胞周期驱动因子、基质重塑酶和细胞间信号因子,有助于临床医生优化剂量和时机等治疗变量。

局限性

  • 原代人类子宫内膜样本量小(N=23),分为四个患者组(每组N=5至6)。
  • 所有参与者均为32至47岁绝经前女性,其中多数属于高龄生殖年龄 category(>35岁)。
  • 尽管研究使用原代子宫内膜细胞并提示HPL可能对RIF和薄型子宫内膜有效,但这些体外发现需在体内验证。
  • 虽然研究提示PRP和HPL含有相似的生长因子环境,但需要随机对照试验评估和比较商业HPL作为aPRP治疗替代方案的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Which biological pathways are modulated by primary human endometrial cells in response to in vitro treatment with non-autologous human platelet lysate (HPL)? SUMMARY ANSWER: HPL treatment stimulates endometrial growth and trophoblast attachment by activating cell proliferation, and modulating cell-cell signaling and extracellular matrix organization. WHAT IS KNOWN ALREADY: There is currently no standard therapy for recurrent implantation failure (RIF), and existing treatments have variable effectiveness and do not consistently improve clinical pregnancy rates. Intrauterine infusion of autologous platelet-rich plasma (aPRP), before embryo transfer, promotes endometrial growth and may be the most effective immunomodulatory intervention to significantly improving pregnancy outcomes in RIF patients. HPL is a commercially available, pooled, and cell debris-cleared derivative of PRP suitable for cell culture. STUDY DESIGN, SIZE, DURATION: Cross-sectional (control versus treatment) study including five non-RIF (control) patients and 18 RIF patients. The 18 RIF patients were categorized into two sub-groups: RIF and RIF including thin endometrium (TE). PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometrial tissue was collected from pre-menopausal women (32-47 years of age) during routine biopsy procedures at the CReATe Fertility Centre, Toronto. Primary endometrial epithelial (EECs) and stromal cells (ESCs) were enzymatically isolated, cultured separately, and treated for 48 h with either serum-free media (SFM) as the untreated control, or SFM supplemented with 1% HPL (EECs), or 10% HPL (ESCs). Cell proliferation was assessed by metabolic assay and immunocytochemistry for Ki-67 expression. Following 48-h treatment, total RNA was isolated from untreated and treated cells to prepare pooled RNA libraries, which were then subjected to RNA sequencing (150 cycles paired-end). Differential gene expression was performed using the DESeq2 package and RStudio/R. Significant differentially expressed genes were determined with the following cut-off values: log2FoldChange >|2| and Padj <0.05. Pathway enrichment analysis was then performed with Enrichr (Reactome 2022 database) to identify enriched pathways. After 48-h treatment with SFM or HPL, a trophoblast attachment assay was also performed with fluorescently labeled HTR-8/SVneo trophoblast spheroids, where spheroids were seeded on top of pre-treated EEC monolayers for a 1-h incubation to allow for attachment. Fluorescent microscopy and ImageJ software were used to image and quantify the total number of seeded and attached spheroids. MAIN RESULTS AND THE ROLE OF CHANCE: Treatment with non-autologous HPL for 48 h significantly increased EEC proliferation by 1.24- to 1.49-fold (P < 0.05) in all groups. ESCs showed a significant proliferation increase of 1.29-fold in the proliferative phase RIF group and 1.92-fold in the secretory phase RIF+TE group (P < 0.05). HPL treatment upregulated 45 genes in EECs, including MMP1, MMP9, and ADAMTS18, while 378 genes were upregulated in ESCs, such as BUB1, CDK1, MKI67, and PLK1. Twenty-two common genes were significantly upregulated in both cell types. EECs had 30 downregulated genes, including KL and ADRA2A, while ESCs had 429 downregulated genes, such as PTGIS, PTGDS, and PTGES, with seven common genes downregulated in both cell types. Pathway enrichment analysis revealed that upregulated pathways in EECs included extracellular matrix organization and degradation, while ESCs showed enrichment in cell cycle (mitotic), cell cycle checkpoints, and extracellular matrix degradation. Downregulated pathways included receptor signaling of the fibroblast growth factor receptor 1 in EECs, prostaglandin synthesis in ESCs, and G-protein coupled receptor signaling in both cell types. HPL treatment also increased primary EEC attachment to trophoblast spheroids compared to the untreated control. This increased attachment was consistent in EECs from RIF patients, regardless of endometrial thickness, with a 26% increase (from 42.58% to 68.90%, P < 0.01) in RIF cultures and a significant 29% increase (from 57.52% to 86.5%, P < 0.01) in RIF+TE cultures. LARGE SCALE DATA: Raw sequencing and count data have been deposited under GEO accession number GSE279514. LIMITATIONS, REASONS FOR CAUTION: One limitation is the small sample size of primary human endometrial samples (N = 23), divided into four patient groups (N = 5-6 per group). Additionally, all participants were pre-menopausal women aged 32-47 years, most of whom fall into the advanced reproductive age category (>35 years), a group often recommended for infertility assessment after 6 months of unsuccessful conception attempts. Although our study utilized primary endometrial cells and indicates that HPL may be an effective treatment for RIF and TE, these in vitro findings need to be validated in vivo. While research from our group and others suggests that PRP and HPL contain a similar growth factor milieu, randomized controlled trials are necessary to evaluate and compare the efficacy of commercial HPL as a treatment alternative to aPRP. WIDER IMPLICATIONS OF THE FINDINGS: Our data provide the first detailed map of the signaling and extracellular-matrix programs that platelet derivatives activate in primary endometrial cells, offering a mechanistic bridge between the growing clinical use of platelet-rich plasma and its observed improvements in implantation. By clarifying which pathways (chiefly cell-cycle drivers, matrix remodeling enzymes, and intercellular signaling factors) are engaged, the study equips clinicians to refine treatment variables such as dose and timing, and highlights actionable biomarkers that could be monitored to verify a receptive endometrial response. At the scientific level, these insights shift the focus from empirical application to rational modulation of endometrial paracrine signaling, guiding the design of next-generation platelet formulations or synthetic analogs that replicate the same molecular signature with greater consistency and safety. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the CReATe Fertility Centre.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Nguyen TTN, Kwok YSS, Zhang C, et al. Unveiling the molecular mechanisms of human platelet lysate in enhancing endometrial receptivity. Hum Reprod. 2025. PMID: 40663777. doi:10.1093/humrep/deaf118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。